Major Estimate Revision • Aug 13
Consensus revenue estimates fall by 83% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$4.13m to US$710.0k. Forecast losses increased from -US$2.82 to -US$3.57 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$31.14 to US$27.57. Share price rose 5.2% to US$14.07 over the past week. Announcement • Jul 30
Evommune Initiates Phase 2b Clinical Trial Of MRGPRX2 Inhibitor EVO756 In Migraine Prophylaxis Evommune, Inc. announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine. MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology. EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) that trigger migraine signal through MRGPRX2. The Phase 2b trial is a global, randomized, double-blind, placebo-controlled, dose-ranging study evaluating EVO756 in adults with refractory migraine experiencing =6 migraine days per month. Approximately 330 patients will be randomized across two active dose arms and placebo for 12 weeks of treatment. The trial is exploring daily doses of up to 100 mg. The primary endpoint of the Phase 2b trial is the mean change from baseline in monthly migraine days (MMD). Key secondary endpoints include the proportion of patients achieving =50% and =75% reductions in MMD, change from baseline in monthly headache days, and monthly acute migraine medication use. Exploratory endpoints include patient subtyping, changes in migraine-related biomarkers, and changes in migraine-specific quality of life measures. EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Evommune seeks to produce the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases, including atopic dermatitis (AD) and migraine, as well as other potential indications. Recent Insider Transactions • Jul 09
Independent Director recently bought US$133k worth of stock On the 7th of July, Arthur Kirsch bought around 10k shares on-market at roughly US$13.30 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$150k more in shares than they have sold in the last 12 months. 
